Cidara Therapeutics company information, Employees & Contact Information

Cidara Therapeutics to Participate in November Investor Conferences GlobeNewswire

Cidara Therapeutics (NASDAQ: CDTX) to join Nov. 11 & 17 Guggenheim, Jefferies events Stock Titan

Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic Yahoo Finance

Cidara Nets $339M BARDA Funding San Diego Business Journal

Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025 Stock Titan

Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025 The Manila Times

Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza Yahoo Finance

Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025 Stock Titan

Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025 GlobeNewswire

Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025 GlobeNewswire

Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025 GlobeNewswire

Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations GlobeNewswire

Cidara Therapeutics to Present Clinical Phase 2b Data and GlobeNewswire

Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting GlobeNewswire

$339M BARDA Award: Cidara Advances CD388 Manufacturing, $58M Base to Onshore U.S. Supply Stock Titan

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results GlobeNewswire

Cidara Therapeutics (CDTX) Stock Soars After $339M BARDA Flu-Drug Deal – Is CD388 the Next Big Flu-Fighter? ts2.tech

Cidara Therapeutics (NASDAQ: CDTX) 2025 Investment Analysis – Will This Anti‑Flu Innovator Keep Soaring? ts2.tech

Biotech Innovator Cidara Therapeutics to Showcase Cloudbreak Platform at Two Global Healthcare Conferences Stock Titan

Cidara Announces Closing of Upsized Public Offering and GlobeNewswire

Cidara Announces Proposed Public Offering of Common Stock GlobeNewswire

Breakthrough Flu Prevention Drug CD388 Data: Cidara Therapeutics Reveals Phase 2b Results at Major Conference Stock Titan

Cidara Announces Pricing of Upsized Public Offering of Common Stock GlobeNewswire

Cidara Therapeutics Sets Q2 Earnings Date: Key Updates on DFC Immunotherapy Platform Expected Stock Titan

Cidara Therapeutics to Host Virtual R&D Day to Discuss GlobeNewswire

Cidara Therapeutics Reveals $48.71 Per Share Inducement Grants Worth Nearly $600K Stock Titan

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results GlobeNewswire

Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors ts2.tech

Cidara Therapeutics Announces Promotion of Nicole GlobeNewswire

Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology GlobeNewswire

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results GlobeNewswire

Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer GlobeNewswire

Cidara Therapeutics Announces $105 Million Private Placement GlobeNewswire

Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388 GlobeNewswire

Cidara Therapeutics Reacquires Global Development and GlobeNewswire